Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
An AI biology platform has identified five promising therapeutic targets for Alzheimer's disease by analyzing the NAD⁺-mitophagy axis — a key pathway in brain aging and neurodegeneration. The study, published in Alzheimer's & Dementia, found that molecular changes in these pathways appear early in disease progression and may even be detectable via blood tests, opening the door to earlier diagnosis and new treatments.
A new study published in Alzheimer's & Dementia is turning heads in the neuroscience world. Researchers from Insilico Medicine, the University of Oslo, and Akershus University Hospital used an AI-driven biology platform called PandaOmics to analyze gene expression across 12 brain regions, cerebrospinal fluid, and blood — comparing healthy aging with four major neurodegenerative diseases: Alzheimer's, Parkinson's, Huntington's, and ALS.
The team zeroed in on the NAD⁺-mitophagy axis — a cellular pathway critical for mitochondrial health and energy metabolism — and found that disruptions in this system are present early in disease progression. Crucially, some of these molecular changes were detectable in blood samples, suggesting potential for non-invasive early biomarkers. PandaOmics evaluated over 100 candidate genes and prioritized five therapeutic targets for Alzheimer's: ULK1, OPA1, LAMP2, MFN1, and ATP6V0E1. Lab experiments confirmed the AI's predictions — boosting OPA1 activity improved cell survival and reduced toxic Tau buildup, while silencing MFN1 and LAMP2 worsened it.
Key Takeaways:
Why it matters: Drug discovery for Alzheimer's has long been a challenging space with a high rate of trial failures. This AI-plus-wet-lab approach offers a faster, more targeted path to identifying therapies — and the blood biomarker angle could transform how early we catch the disease.
